<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560313</url>
  </required_header>
  <id_info>
    <org_study_id>V72P4</org_study_id>
    <secondary_id>2007-001563-29</secondary_id>
    <nct_id>NCT00560313</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults</brief_title>
  <official_title>A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to evaluate safety, tolerability and immunogenicity of three doses of
      Novartis 4CMenB and of one dose of Novartis Meningococcal ACWY vaccine when administered to
      healthy at-risk adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer of the Meningococcal B Vaccine Against the Different Strains at One Month After First, Second and Third Vaccination.</measure>
    <time_frame>One month after vaccinations</time_frame>
    <description>Geometric mean titers(GMT) and the respective confidence intervals measured after each vaccination against the three different meningococcal strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Participants With Serum Bactericidal Activity of the Meningococcal B Vaccine Against Different Strains at One Month After First, Second and Third Vaccination.</measure>
    <time_frame>One month after vaccinations</time_frame>
    <description>Percentage of participants with serum bactericidal activity (SBA) of the Meningococcal ACWY vaccine at one month after vaccination against A, C, W-135 and Y strains. Bactericidal activity (% ≥ 1:4, i.e., percentage of subjects with BCA titer ≥ 1:4; % ≥ 1:8, i.e. percentage of subjects with BCA titer ≥ 1:8) against a panel of genetically distinct meningococcal B strains:
prior to the first vaccination
30 days following the first, second, prior to the third and 30 days after the third vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of the Meningococcal ACWY Vaccine at One Month After Vaccination.</measure>
    <time_frame>One month after vaccinations</time_frame>
    <description>Geometric mean titer (GMT) of the Meningococcal ACWY Vaccine at One Month After the Immunization against the A, C, W-135 and Y strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Activity of the Meningococcal ACWY Vaccine at One Month After Vaccination</measure>
    <time_frame>One month after vaccinations</time_frame>
    <description>Percentage of participants with serum bactericidal activity (SBA) of the Meningococcal ACWY vaccine at one month after vaccination against A, C, W-135 and Y strains. Bactericidal activity (% ≥ 1:4, i.e., percentage of subjects with BCA titer ≥ 1:4; % ≥ 1:8, i.e. percentage of subjects with BCA titer ≥ 1:8) against a panel of genetically distinct meningococcal B strains:
prior to the first vaccination
30 days following the first, second, prior to the third and 30 days after the third vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Reported Solicited Local and Systemic Reactions Post Vaccination.</measure>
    <time_frame>One month after vaccinations</time_frame>
    <description>The number of subjects who reported solicited reactions after the administration of the Meningococcal B vaccine at a 0, 2, 6-month schedule and the administration of the Meningococcal A, C, W, and Y vaccine at month 7.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>4CMenB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men ACWY CRM</intervention_name>
    <description>A single dose of a 0.5 mL injectable solution</description>
    <arm_group_label>MenACWY CRM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4CMenB</intervention_name>
    <description>All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.</description>
    <arm_group_label>4CMenB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults,18 through 50 years of age, who were or might be routinely exposed to
             N. meningitidis cultures

        Exclusion Criteria:

          -  Previous ascertained or suspected disease caused by N. meningitidis;

          -  Pregnancy or breastfeeding;

          -  History of any anaphylactic shock, asthma, urticaria or other allergic reaction after
             previous vaccinations or known hypersensitivity to any vaccine component;

          -  Any present or suspected serious acute or chronic disease

          -  Known or suspected autoimmune disease or impairment /alteration of immune function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda USL 7 of Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011 Mar;18(3):483-6. doi: 10.1128/CVI.00304-10. Epub 2010 Dec 22.</citation>
    <PMID>21177912</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2007</study_first_submitted>
  <study_first_submitted_qc>November 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2007</study_first_posted>
  <results_first_submitted>June 6, 2011</results_first_submitted>
  <results_first_submitted_qc>June 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2011</results_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal disease</keyword>
  <keyword>prevention</keyword>
  <keyword>vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at one site in Italy and one site in Germany.</recruitment_details>
      <pre_assignment_details>Approximately 250 adults were planned to be enrolled in this study but only a total of 54 subjects were enrolled after the screening for the inclusion and exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>4CMenB</title>
          <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Events or Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4CMenB</title>
          <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer of the Meningococcal B Vaccine Against the Different Strains at One Month After First, Second and Third Vaccination.</title>
        <description>Geometric mean titers(GMT) and the respective confidence intervals measured after each vaccination against the three different meningococcal strains.</description>
        <time_frame>One month after vaccinations</time_frame>
        <population>The analysis was done on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB (44/76-SL)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. Response was measured against (44/76-SL) strain</description>
          </group>
          <group group_id="O2">
            <title>4CMenB (5/99)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. Response was measured against the (5/99)strain</description>
          </group>
          <group group_id="O3">
            <title>4CMen B (NZ98/254)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. Response was measured against the (NZ98/254)strain.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of the Meningococcal B Vaccine Against the Different Strains at One Month After First, Second and Third Vaccination.</title>
          <description>Geometric mean titers(GMT) and the respective confidence intervals measured after each vaccination against the three different meningococcal strains.</description>
          <population>The analysis was done on the per protocol population.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.7" upper_limit="3.5"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.6" upper_limit="3.2"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1.3" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post dose 1 titer (N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="15" upper_limit="72"/>
                    <measurement group_id="O2" value="29" lower_limit="14" upper_limit="60"/>
                    <measurement group_id="O3" value="23" lower_limit="11" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post dose 2 titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="71" upper_limit="121"/>
                    <measurement group_id="O2" value="144" lower_limit="108" upper_limit="193"/>
                    <measurement group_id="O3" value="32" lower_limit="21" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before dose 3 titer(N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="15" upper_limit="47"/>
                    <measurement group_id="O2" value="37" lower_limit="26" upper_limit="53"/>
                    <measurement group_id="O3" value="9.4" lower_limit="4.1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post dose 3 titer (N=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="68" upper_limit="131"/>
                    <measurement group_id="O2" value="269" lower_limit="205" upper_limit="354"/>
                    <measurement group_id="O3" value="30" lower_limit="18" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Participants With Serum Bactericidal Activity of the Meningococcal B Vaccine Against Different Strains at One Month After First, Second and Third Vaccination.</title>
        <description>Percentage of participants with serum bactericidal activity (SBA) of the Meningococcal ACWY vaccine at one month after vaccination against A, C, W-135 and Y strains. Bactericidal activity (% ≥ 1:4, i.e., percentage of subjects with BCA titer ≥ 1:4; % ≥ 1:8, i.e. percentage of subjects with BCA titer ≥ 1:8) against a panel of genetically distinct meningococcal B strains:
prior to the first vaccination
30 days following the first, second, prior to the third and 30 days after the third vaccination</description>
        <time_frame>One month after vaccinations</time_frame>
        <population>The analysis was done on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB (44/76-SL)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. Response was measured against (44/76-SL) strain</description>
          </group>
          <group group_id="O2">
            <title>4CMenB (5/99)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. Response was measured against the (5/99) strain</description>
          </group>
          <group group_id="O3">
            <title>4CMen B (NZ98/254)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. Response was measured against the (NZ98/254) strain.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants With Serum Bactericidal Activity of the Meningococcal B Vaccine Against Different Strains at One Month After First, Second and Third Vaccination.</title>
          <description>Percentage of participants with serum bactericidal activity (SBA) of the Meningococcal ACWY vaccine at one month after vaccination against A, C, W-135 and Y strains. Bactericidal activity (% ≥ 1:4, i.e., percentage of subjects with BCA titer ≥ 1:4; % ≥ 1:8, i.e. percentage of subjects with BCA titer ≥ 1:8) against a panel of genetically distinct meningococcal B strains:
prior to the first vaccination
30 days following the first, second, prior to the third and 30 days after the third vaccination</description>
          <population>The analysis was done on the per protocol population.</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>titer ≥4 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="23" upper_limit="52"/>
                    <measurement group_id="O2" value="37" lower_limit="23" upper_limit="52"/>
                    <measurement group_id="O3" value="22" lower_limit="11" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥4 (Post dose 1) N=25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="64" upper_limit="95"/>
                    <measurement group_id="O2" value="88" lower_limit="69" upper_limit="97"/>
                    <measurement group_id="O3" value="80" lower_limit="59" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥4 (Post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O3" value="91" lower_limit="79" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥4 (Before dose 3) N=24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="79" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O3" value="67" lower_limit="45" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥4 (Post dose 3) N=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O3" value="92" lower_limit="79" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥8 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="14" upper_limit="41"/>
                    <measurement group_id="O2" value="15" lower_limit="6" upper_limit="29"/>
                    <measurement group_id="O3" value="15" lower_limit="6" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥8 (Post dose 1) N=25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="59" upper_limit="93"/>
                    <measurement group_id="O2" value="76" lower_limit="55" upper_limit="91"/>
                    <measurement group_id="O3" value="72" lower_limit="51" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥8 (Post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O3" value="83" lower_limit="69" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥8 (Before dose 3) N=24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="53" upper_limit="90"/>
                    <measurement group_id="O2" value="100" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O3" value="54" lower_limit="33" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥8 (Post dose 3) N=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O3" value="77" lower_limit="61" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥4 fold increase (Post dose 1) N=25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="59" upper_limit="93"/>
                    <measurement group_id="O2" value="64" lower_limit="43" upper_limit="82"/>
                    <measurement group_id="O3" value="68" lower_limit="46" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥4 fold increase (Post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O3" value="78" lower_limit="64" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥4 fold increase (Before dose 3) N=24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="49" upper_limit="87"/>
                    <measurement group_id="O2" value="75" lower_limit="53" upper_limit="90"/>
                    <measurement group_id="O3" value="46" lower_limit="26" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥4 fold increase (Post dose 3) N=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O3" value="69" lower_limit="52" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of the Meningococcal ACWY Vaccine at One Month After Vaccination.</title>
        <description>Geometric mean titer (GMT) of the Meningococcal ACWY Vaccine at One Month After the Immunization against the A, C, W-135 and Y strains.</description>
        <time_frame>One month after vaccinations</time_frame>
        <population>The analysis was done on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (A)</title>
            <description>1 month postvaccination with quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM (C)</title>
            <description>1 month postvaccination with quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (W-135)</title>
            <description>1 month postvaccination with quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-CRM (Y)</title>
            <description>1 month postvaccination with quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of the Meningococcal ACWY Vaccine at One Month After Vaccination.</title>
          <description>Geometric mean titer (GMT) of the Meningococcal ACWY Vaccine at One Month After the Immunization against the A, C, W-135 and Y strains.</description>
          <population>The analysis was done on the per protocol population.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="34" upper_limit="85"/>
                    <measurement group_id="O2" value="42" lower_limit="27" upper_limit="66"/>
                    <measurement group_id="O3" value="90" lower_limit="58" upper_limit="139"/>
                    <measurement group_id="O4" value="36" lower_limit="16" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serum Bactericidal Activity of the Meningococcal ACWY Vaccine at One Month After Vaccination</title>
        <description>Percentage of participants with serum bactericidal activity (SBA) of the Meningococcal ACWY vaccine at one month after vaccination against A, C, W-135 and Y strains. Bactericidal activity (% ≥ 1:4, i.e., percentage of subjects with BCA titer ≥ 1:4; % ≥ 1:8, i.e. percentage of subjects with BCA titer ≥ 1:8) against a panel of genetically distinct meningococcal B strains:
prior to the first vaccination
30 days following the first, second, prior to the third and 30 days after the third vaccination</description>
        <time_frame>One month after vaccinations</time_frame>
        <population>The analysis was done on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (A)</title>
            <description>1 month postvaccination with quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM (C)</title>
            <description>1 month postvaccination with quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (W-135)</title>
            <description>1 month postvaccination with quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-CRM (Y)</title>
            <description>1 month postvaccination with quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Activity of the Meningococcal ACWY Vaccine at One Month After Vaccination</title>
          <description>Percentage of participants with serum bactericidal activity (SBA) of the Meningococcal ACWY vaccine at one month after vaccination against A, C, W-135 and Y strains. Bactericidal activity (% ≥ 1:4, i.e., percentage of subjects with BCA titer ≥ 1:4; % ≥ 1:8, i.e. percentage of subjects with BCA titer ≥ 1:8) against a panel of genetically distinct meningococcal B strains:
prior to the first vaccination
30 days following the first, second, prior to the third and 30 days after the third vaccination</description>
          <population>The analysis was done on the per protocol population.</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>titers ≥ 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="78" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="85" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="85" upper_limit="100"/>
                    <measurement group_id="O4" value="83" lower_limit="61" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titers ≥8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="78" upper_limit="100"/>
                    <measurement group_id="O2" value="96" lower_limit="78" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="85" upper_limit="100"/>
                    <measurement group_id="O4" value="83" lower_limit="61" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Reported Solicited Local and Systemic Reactions Post Vaccination.</title>
        <description>The number of subjects who reported solicited reactions after the administration of the Meningococcal B vaccine at a 0, 2, 6-month schedule and the administration of the Meningococcal A, C, W, and Y vaccine at month 7.</description>
        <time_frame>One month after vaccinations</time_frame>
        <population>The analysis was done on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB (Post Dose 1)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. We report Numbers (%) of Subjects with Local and Systemic Reactions as indicators of Reactogenicity, by Vaccination post dose 1</description>
          </group>
          <group group_id="O2">
            <title>4CMenB (Post Dose 2)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. We report Numbers (%) of Subjects with Local and Systemic Reactions as indicators of Reactogenicity, by Vaccination post dose 2.</description>
          </group>
          <group group_id="O3">
            <title>4CMenB (Post Dose 3)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. We report Numbers (%) of Subjects with Local and Systemic Reactions as indicators of Reactogenicity, by Vaccination post dose 3.</description>
          </group>
          <group group_id="O4">
            <title>Men ACWY-CRM (One Dose)</title>
            <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB. We report Numbers (%) of Subjects with Local and Systemic Reactions as indicators of Reactogenicity, by Vaccination post one dose of Men ACWY vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Solicited Local and Systemic Reactions Post Vaccination.</title>
          <description>The number of subjects who reported solicited reactions after the administration of the Meningococcal B vaccine at a 0, 2, 6-month schedule and the administration of the Meningococcal A, C, W, and Y vaccine at month 7.</description>
          <population>The analysis was done on the per protocol population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection pain (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection pain (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic, antipyretic medicine used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the duration of the study (8 months).</time_frame>
      <desc>Adverse events categorized as systematic assessment is defined as solicited adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>4CMenB (1st Vaccination)</title>
          <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB.
Post dose 1.</description>
        </group>
        <group group_id="E2">
          <title>4CMenB (2nd Vaccination)</title>
          <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB.
Post dose 2.</description>
        </group>
        <group group_id="E3">
          <title>4CMenB (3rd Vaccination)</title>
          <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB.
Post dose 3.</description>
        </group>
        <group group_id="E4">
          <title>Men ACWY-CRM</title>
          <description>All participants were administered three doses of 4CMenB (0,2,6 months) and all were administered a single dose of MenACWY-CRM 1 month after the third dose of 4CMenB.
Post dose 1 MenACWY.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>After first vaccination</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

